Geneditierung

Gene Editing is a thematic segment focused on technologies that precisely modify DNA to treat disease, engineer cells, and enhance biological systems. Core tracks include CRISPR and next‑gen editors (base/prime), in vivo and ex vivo therapeutics, delivery platforms (AAV/LNP), cell and gene therapy pipelines, enabling reagents and tools, and agricultural and synthetic biology applications.The sector's total market cap is 127.85 billion USD, with a 24h change of +0.84%. Among 3 constituents, 3 are up (100.00%) and 0 are down (0%). The top gainer is CRISPR Therapeutics AG (CRSP), with a 24h increase of +1.55%.Gene editing ticked higher on narrow breadth, with strength centered in leaders. Near term, trade top names; longer term, accumulate on key clinical milestones and supportive funding or rate conditions.